Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ReShape Lifesciences, Inc. - Common Stock (NQ:RSLS)

2.730 -0.620 (-18.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ReShape Lifesciences, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Reshape Lifesciences Earnings Perspective: Return On Capital Employed
 
Via Benzinga
ReShape Lifesciences Announces 1-for-50 Reverse Stock Split Effective as of Commencement of Trading on December 23, 2022
From ReShape Lifesciences Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 89 companies set new 52-week lows. 
Via Benzinga
ReShape Lifesciences' GIBI HD Calibration Tubes Scores FDA Approval For Tummy Tuck Procedures
 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 298 companies achieved new lows for the year. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
ReShape Lifesciences(TM) (NASDAQ: RSLS) Featured in Coverage of Investor Summit Group’s Q4 Event
Via Investor Brand Network
ReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Conference Call to be Held at 8:00 am ET Today 
From ReShape Lifesciences Inc
Via GlobeNewswire
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million. 
Via Benzinga
ReShape Lifesciences Announces $750,000 Registered Direct Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences™ to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update
Conference Call to be Held at 8:00 am ET on Monday, November 14, 2022 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at ObesityWeek®
Stimulation of Vagus Celiac Fibers with Concurrent High Frequency Alternating Current Block of Hepatic Fibers Decreases Glucose Variability in a Swine Model of Type 2 Diabetes 
From ReShape Lifesciences Inc
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 236 companies set new 52-week lows. 
Via Benzinga
ReShape Lifesciences to Present at the Q4 Investor Summit
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences™ Announces Publication of Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) System in Peer Reviewed, Frontiers in NeuroScience
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences™ Announces Release of a Positive Consensus Statement on Lap-Band® Use and Lap-Band® Aftercare Management by the American Society of Metabolic and Bariatric Surgery (ASMBS)
From ReShape Lifesciences Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Reshape Lifesciences (NASDAQ:RSLS) shares increased by 12.7% to $0.34 during Monday's after-market session. The market value of their outstanding shares is at $1.2 million. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 44 companies hit new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Reshape Lifesciences (NASDAQ:RSLS) stock increased by 10.1% to $0.39 during Monday's after-market session. The company's market cap stands at $1.3 million. 
Via Benzinga
Reshape Lifesciences's Return On Capital Employed Overview
Benzinga Pro data, Reshape Lifesciences (NASDAQ:RSLS) reported Q2 sales of $2.89 million. Earnings fell to a loss of $9.58 million, resulting in a 16.57% decrease from last quarter. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 122 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 37 stocks hit new 52-week lows. 
Via Benzinga
Reshape Lifesciences Earnings Outlook
  Reshape Lifesciences (NASDAQ:RSLS) is set to give its latest quarterly earnings report on Monday, 2022-08-15. Here's what investors need to know before the announcement. 
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
ReShape Lifesciences Shares Soar As FDA Announced Clearance To GIBI HD Calibration Tubes In Weight Loss Procedures
The U.S. Food and Drug Administration (FDA) has announced 510(k) clearance to ReShape Lifesciences’ (NASDAQ: RSLS) Gastro Intestinal Balloon Indicator (GIBI HD) calibration tube for use in gastric and... 
Via Benzinga
Earnings Scheduled For August 15, 2022
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter. 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.